



ROAR, the University of East London Institutional Repository: http://roar.uel.ac.uk  
 
This paper is made available online in accordance with publisher policies. Please 
scroll down to view the document itself. Please refer to the repository record for this 
item and our policy information available from the repository home page for further 
information. 
 
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription.  
 
Author(s): K. Soar, A. Parrott and J. Turner 
Article Title: Attributions for psychobiological changes in ecstasy/MDMA and 
other polydrug users  
Year of publication: 2009 
Citation: Soar, K., Parrott, A. and Turner, J. (2009) 'Attributions for psychobiological 
changes in ecstasy/MDMA and other polydrug users'. Journal of 
Psychopharmacology, 23(7), pp. 745-758. 
 
Link to published version:  
http://dx.doi.org/10.1177/0269881108092594  
 
Publisher statement:  
© Sage 2009. The published version in Journal of Psychopharmacology is online 
since 17 July 2008 at http://jop.sagepub.com/  
 
Information on how to cite items within roar@uel: 
http://www.uel.ac.uk/roar/openaccess.htm#Citing  
 INTRODUCTION   
 
Recreational ecstasy (MDMA) use has been associated with a number of psychiatric symptoms 
and psychobiological problems (Milani et al, 2000; MacInnes et al, 2001; Parrott et al, 2001; 
Verheyden et al, 2003; Soar et al, 2006; Rodgers et al, 2006).  A range of measures have been 
used to record such psychobiological problems, including clinical measures such as the Symptom 
Checklist-90 (Parrott, Sisk and Turner, 2000; Parrott et al, 2001; Dugherio et al, 2001;Milani et al 
2004), the Symptom Checklist-90-Revised (Daumann et al, 2001 & 2004; Morgan et al, 2002; 
Thomasius et al, 2006), and specific measures of depression (MacInnes et al, 2001; de Win et al, 
2006; Lamers et al, 2006) and anxiety (Lamers et al, 2006).  These studies have shown that 
ecstasy users often demonstrate higher levels of psychopathology than non-ecstasy user control 
groups.  However, only a limited number of studies have addressed what problems ecstasy users 
specifically attribute ‘off-drug’ to their current and past ecstasy use.  Cohen (1995) showed that a 
number of ecstasy users reported both psychological and physical long term recurring effects 
which they attributed to their ecstasy use, including depersonalisation, insomnia and depression. 
Parrott et al (2002) also reported ecstasy-attributed problems as reported by novice (1-9), 
moderate (10-99) and heavy (+100) ecstasy users, including depression, memory problems, mood 
fluctuation, poor concentration, infections, tremors/twitches and weight loss, which were all 
shown to be significantly associated with the extent of ecstasy use.  Rodgers et al (2006) reported 
a variety of ‘off-drug’ problems attributed to ecstasy in 209 ecstasy users, similar to those 
reported by Parrott et al (2002), and confirmed the strong association with lifetime 
Ecstasy/MDMA use.  Rodgers et al (2006) also reported that users attributed a number of ‘off-
drug’ perceived positive effects to their ecstasy consumption; including ‘a changed outlook on 
life’, ‘understanding of self’, and improved relationships, sociability, psychological functioning 
 and healthiness.  However, none of these studies explored the role of other drugs, combinations 
of ecstasy with other drugs, or related non-drug factors, in the attributions made by ecstasy users.     
 
Epidemiological studies show that individuals who regularly take ecstasy are also likely to be 
polydrug users (Webb et al, 1996; Pederson & Skrondal, 1999; Topp et al, 1999; Sherlock and 
Connor, 1999; Winstock et al, 2001; Strote et al, 2002; Arria et al, 2002; Scholey et al, 2004; 
Sumnall et al, 2004; Hopper et al, 2006).  The most commonly reported co-used substances are 
tobacco, alcohol, cannabis, amphetamine and cocaine (Sherlock and Connor, 1999; Gouzoulis-
Mayfrank and Daumann, 2006), although increasing use of ecstasy appears to also be associated 
with more widespread and heavier use of other stimulants and hallucinogens (Scholey et al, 
2004). These drugs have also been linked with negative psychopathological profiles (Mass et al, 
2001; Lavik & Onstad, 1986).  As such, it’s clear that polydrug use is an important potential 
influence for the psychobiological consequences of ecstasy/MDMA consumption (Parrott, 2006). 
Indeed, Parrott et al (2001) found that the heavier the polydrug use alongside ecstasy the higher 
the level of self-reported psychological symptoms.  Other studies have also shown that elevated 
psychopathology in ecstasy users appears to be associated more with polydrug use (Medina and 
Shear, 2007), and in some cases specifically cannabis rather than ecstasy (Daumann et al, 2001; 
Morgan et al., 2002; Rosier and Sahakian, 2004; Daumann et al, 2004). A possible combination 
effect of ecstasy and cannabis use is also supported by recent findings from Milani et al (2005), 
who reported that heavy cannabis use appeared to exacerbate psychobiological problems in 
ecstasy users, and Lamers et al (2006) who found that individuals who used both ecstasy and 
cannabis reported more symptoms of anxiety and depression than non-drug users and cannabis 
only users. In a review of this topic, Parrott (2006) showed that the deficits of Ecstasy/MDMA 
users generally remained significant after controlling for these other psychoactive drugs, although 
it was emphasised that these other drugs would also be having important contributory effects.   
  
The present study continues this exploration of chronic ‘off-drug’ experiences, using a large scale 
survey which sought to determine which drugs were associated with the long-term psychological 
and physical effects reported by some ecstasy-polydrug users. The volunteers were asked to 
indicate which drug or drug combinations, if any; they attributed to changes in their life 
experiences.   These ‘life experience’ items were drawn from previous empirical and subjective 
literature into ecstasy/MDMA (Liechti et al 2000; Gamma et al, 2000; Cami et al, 2000; Liechti 
and Vollenweider, 2001; Cohen et al, 1995; Parrott et al, 2002).  This novel manipulation then, 
tests the assumption that such changes result from ecstasy use, over and above the effects of other 
substances, by transposing these positive and negative ‘symptoms’ into questions and exploring 
the perceptions and attributions to different drugs amongst polysubstance users themselves. 
 
Another aim  was to investigate possible differences in drug-attributions between ecstasy users 
that did not report problems associated with their ecstasy use (non-problematic users), compared 
with ecstasy users who did reported problems with their ecstasy use (problematic users).  Fox et 
al (2001) and Soar et al (2006) have previously compared ‘problematic’ and ‘non-problematic’ 
ecstasy users, and found differences in the perceived psychological problems attributed to their 
ecstasy consumption; and to a degree such differences have been accounted for by premorbid 
characteristics and patterns of ecstasy use. However, the role of other polydrug use has not 







Participants were recruited through a number of techniques, including recruitment notices 
throughout the University of East London’s e-mail system, posters around the University of East 
London and various clubs throughout London, and via an advertisement in the ‘Big Issue’ 
magazine   The call for participants asked for any ecstasy and/or other drug users (including 
alcohol and nicotine) interested in contributing to psychological research to contact us or visit our 
website.  The  exclusion criteria were: under the age of 18, currently taking any psychotropic 
medication, epilepsy or any other form of brain injury. 
 
Two-hundred and eighty-eight volunteers participated in the study: 111 (37 male, 74 female) 
participants who reported no past drug use, other than alcohol and nicotine; 62 (27 male, 35 
female) polydrug users who had no history of ecstasy use but otherwise had used other illicit 
drugs; 62 (33 male, 29 female) ‘non-problematic’ ecstasy users, who reported ecstasy and other 
drug use but did not report problems from their past ecstasy use; and 53 (25 male, 28 female) 
‘problematic’ ecstasy users, who reported ecstasy and other polydrug use and also indicated that 
they had experienced problems which they attributed to ecstasy use.  All participants were 
allocated to these groups using a post hoc method: problematic ecstasy users were distinguished 
from non-problematic users by answering ‘yes’ to the question, ‘Have you experienced any 
problems, which you attribute to your ecstasy use?’ All participants gave written informed 




 Each volunteer completed a questionnaire using either a hard copy (n= 46) or one accessed and 
submitted on-line (n=242) via http://homepages.uel.ac.uk/K.Soar/ecstasy_qa.htm (part of the 
University of East London’s web-site).   
 
Health & Drug Use Questionnaire 
 
This questionnaire (used previously in Soar et al, 2006), consisted of questions concerning 
personal history of participants own, and their immediate family’s, psychiatric history.  Questions 
pertaining to past drug history were those that make up the UEL drug use questionnaire (Parrott, 
Sisk and Turner, 2000),    Ecstasy users were required to provide further information concerning 
patterns of ecstasy use: including information on the duration of ecstasy use, the last time taken, 
the average number of ecstasy tablets consumed in one occasion and the largest number 
consumed in one occasion and an estimation of their lifetime consumption  .  This was followed 
by the question which allowed post hoc group allocation to problematic and non-problematic 
ecstasy groups.  Those ecstasy users that indicated they had or did attribute problems to ecstasy 
use were further asked whether any of these changes had led them to seek help and/or advice 
from a health professional or organisation, and to indicate which particular service (e.g. GP, 
Clinical psychologist, psychiatrist, drugs clinic/services or counselling).  Again all of these 
questions have previously been utilised to ascertain patterns of ecstasy use and indication of 
problems in ecstasy users (e.g. Soar et al, 2006). 
  
Life changes Questionnaire 
 
This questionnaire was designed specifically for this study, it required all participants to indicate 
whether or not they had experienced a list of 7 positive and 21 negative changes in their life 
 experiences, when not under the influence of drugs or alcohol.  These life experiences were in 
fact psychological and physical effects, which have previously been shown to be associated with 
ecstasy (MDMA).  The items were drawn from a review of the empirical and subjective effects 
associated with ecstasy use (Liechti et al 2000; Gamma et al, 2000; Cami et al, 2000; Liechti & 
Vollenweider, 2001; Cohen et al, 1995; Parrott et al, 2002).  However, wording of the questions 
did not allude specifically to this connection with ecstasy/MDMA: “Below are a list of positive 
and negative life experiences, please  indicate whether you have experience any of these (when 
not under the influence of drugs or alcohol) and what you attribute this change to the most by 
circling the appropriate statements”.  This allowed for exploration of whether these effects are 
reported by all participants, regardless of their ecstasy use, and whether these so called ‘ecstasy 
effects’ are in fact effects associated or attributed to other, different drugs, amongst those 
polydrug users.  The imbalance in the number of positive and negative items used reflects current 
bias in the research literature on the investigation into the negative effects of ecstasy/MDMA.  
Participants were shown a list of the 28 positive and negative (life experience/ecstasy effects) 
items followed by 8 options to circle; ‘other non-drug factor’, ‘ecstasy’, ‘amphetamine’, 
‘cocaine’, ‘LSD’, ‘Cannabis’, ‘alcohol’ or ‘no change experienced’. Those specific drug options 
were chosen because they are the most common drugs used by recreational ecstasy polydrug 
users and also in combination with ecstasy (e.g. Scholey et al, 2004; Gouzouluis-Mayfrank and 
Daumann, 2006).  Cronbach’s’ alpha reliability analyses for the scale (all 28 items) indicates 




 Data analysis was conducted using SPSS 10.  One-way ANOVAs were performed on the 
demographic data to assess whether there were any group differences between the 
alcohol/nicotine group, polydrug controls, non-problematic and problematic ecstasy users.   
Where there were violations of homogeneity of variance (e.g. age and rating of health) the 
Kruskall Wallis test was employed.   Post hoc pair-wise comparisons between groups were 
conducted using the Tukey’s HSD range statistic and Mann-Whitney test for the non-parametric 
equivalent, with the error rate set at 0.017 to reduce the risk of type 1 errors.  Chi-squared tests 
were used to investigate any significant group differences with questions regarding gender, 
ethnicity, reported psychiatric history and family psychiatric history. 
 
Drug use data violated the assumption of homogeneity of variance, despite attempts at 
transforming the data.  Therefore Kruskall Wallis tests were employed.  The independent samples 
t-test was used to assess differences in patterns of ecstasy use between the two ecstasy using 
groups.   
 
Data concerning the positive and negative changes to life experiences and which, if any, drugs 
they attributed these changes to, are reported as percentages.  It was deemed inappropriate to 
conduct detailed inferential analyses on all of this data for a number of reasons.  The first was 
that levels of drug use differed considerably across all four drug using groups.  Secondly, 
respondents sometimes indicated more than one drug for each dimension on the questionnaire, 
yet it was difficult to establish whether they were referring to polydrug use as contributing to this 
change or whether individual drugs per se contributed to this change.  Thirdly, not all cells were 
independent.  Finally, if a chi squared test was conducted the expected frequency would be less 
than 5 on more than 20% of cases; therefore it would not have been statistically viable.  However, 
data concerning the number of respondents, in each of the four groups, who indicated they had 
 experienced a change were analysed using a 4 x 2 Chi Squared test.  Separate 2 x 2 Chi Square 
tests were used to establish where, between the four groups, any statistically significant 
differences lay.  A significance level of 0.008 was used, in order to limit the possibilities of type 
1 errors.  For those respondents in the drug using groups who did indicate a change attributable to 
drug use, a 3 x 2 Chi Squared test was utilised to establish whether there were any significant 
differences between the number of respondents in each group who indicated more than one drug 
as indicative of positive and negative changes.  Separate 2 x 2 chi square tests were used to 
establish which groups differed with the significance level set at 0.02 to reduce possible type 1 
errors.  The effect size (Cohen’s W) and post hoc power calculations of the main group Chi 
square analyses (calculated using G*Power 3) are also given in tables 3 and 4, where appropriate. 
The standard conventions for W are 0.1, 0.3 and 0.5 for small, medium and large effect sizes, 





Group characteristics and drug data 
 
Table 1 show the demographic data for the participants and patterns of drug use and table 2 
indicate the number of participants, by group, who indicated previous individual and family 
psychiatric problems (data previously reported for these participants in Soar et al, 2006).  There 
were no significant group differences for gender or health.  However, there was a significant 
group effect of age [χ2(3) = 19.51, p<0.001], as non-problematic ecstasy users were significantly 
older than alcohol/nicotine group (p=<0.001).  There was a significant difference in reported 
psychiatric history (χ2(3) = 30.71, p<0.001) and family psychiatric history (χ2(3) = 18.84, 
 p<0.001), with a greater number of problematic ecstasy users reporting a psychiatric history 
compared to controls and ecstasy users.  There was also a significant difference in ethnicity 
between groups (χ2(12) = 45.78, p<0.001), with alcohol/nicotine participants showing greater 
ethnic diversity than non-problematic ecstasy and problematic ecstasy users. 
 
[table 1 & 2 ] 
 
There were significant group differences on most levels of reported illegal drug consumption: 
amphetamine, cocaine, crack, LSD, magic mushrooms, poppers, ketamine and current cannabis 
use.  Specifically, polydrug controls reported using significantly less amphetamine, cocaine, 
LSD, magic mushrooms, poppers, ketamine and current cannabis use, compared to non-
problematic ecstasy and problematic ecstasy users; and significantly less crack use compared to 
problematic ecstasy users.   Given that this group of users reported low use of drugs with the 
exception of cannabis, it was deemed appropriate to refer to this group as cannabis using controls 
rather than polydrug controls from here on. Non-problematic ecstasy and problematic ecstasy 
users reported similar consumption of illegal drugs, with the exception of LSD and magic 
mushrooms, where the problematic ecstasy group reported a significantly greater consumption of 
both drugs. 
 
The alcohol/nicotine group reported significantly less tobacco and alcohol use compared to 
cannabis, non-problematic ecstasy and problematic ecstasy users.  Cannabis controls also 
reported significantly less tobacco use compared to non-problematic ecstasy and problematic 
ecstasy users, as well as significantly less alcohol use compared to non-problematic ecstasy users. 
  
Patterns of ecstasy use differed between the two ecstasy using groups.  Problematic ecstasy users 
reported significantly higher lifetime consumption levels of ecstasy [t(113) = -2.31, p = 0.025] , 
average dosage levels [t(109) = -3.09, p = 0.003] and maximum dosage levels [t(109) = -2.90, p = 
0.005] compared to non-problematic ecstasy users.  However, there were no significant 
differences in duration of ecstasy use and length of abstinence periods from ecstasy use between 
the two ecstasy using groups. 
 
Problematic ecstasy users were also asked to indicate whether they had sought some form of help 
for their attributed problems.  32.1% (n = 17) reported that they had, the most common help 
sought was from a GP (26.4%).  11.3% sought help from a psychiatrist and 9.4% sought help 
from a clinical psychologist or drugs service.  The final 11.3% sought help from a variety of 
other organisations, which included counselling services.  
 




Table 2 shows the number and percentage of alcohol/nicotine users, cannabis controls, non-
problematic and problematic ecstasy users who reported that they had experienced positive and 
negative life changes.  There were highly significant differences between groups for all life 
changes.  Post hoc comparisons are also indicated (table 3), with a significant lower number of 
people in the alcohol/nicotine group reporting experiencing a majority of the positive and 
negative changes compared to cannabis controls, non-problematic and problematic ecstasy user 
 groups.   Cannabis users reported significantly less life experience changes compared to non-
problematic and/or problematic ecstasy users in areas of spiritual enlightenment, enhanced 
sensations, obsessive thoughts, mood swings, depression, anxiety, paranoia, hallucinations, panic 
attacks, weight loss, sleep disruptions, but a greater number of cannabis using controls reported 
memory problems compared to both non-problematic and problematic ecstasy users.  A 
significantly greater number of problematic ecstasy users reported changes in panic attacks, 
depression, paranoia and general illness, compared to non-problematic ecstasy users.  
 
 




Chi squared results indicate that there were significant groups differences in the number of 
people who reported attributing life changes to more than one drug on a majority of life changes  
(table 4).   Of those cannabis using controls who did indicate life changes attributable to drugs, 
they were significantly more likely to attribute these changes to just one drug rather than a 
combination of drugs, compared to the non-problematic and problematic ecstasy users.  This 
finding was relatively consistent across positive and negative life changes, except for spiritual 
enlightenment, confidence loss, backache and sexual problems.  In addition, compared to non-
problematic ecstasy users, a significantly higher number of problematic ecstasy users attributed 
more than one drug to increased empathy, decreased fear, obsessive thoughts, aggression, 
anxiety, paranoia, hallucinations, sexual problems, and general illness, loss of organisational 
skills, memory loss and concentration loss.   
 
 Specific Drugs and Attributions to Positive Life Experience Changes  
 
In attempting to establish which, if any, specific drugs were more likely to be associated by 
participants as being linked to or causing specific changes in behaviour/life experience, 
inferences could only be made by comparing percentages, for reasons stated earlier (tables 5-8).  
Improved social/interpersonal functioning was relatively strongly attributed to alcohol compared 
to any other drug across all four groups, with 18% of alcohol/nicotine users, 45.2% cannabis 
controls, 43.5% non-problematic ecstasy users and 28.3% problematic ecstasy users attributing 
this change to alcohol.  However, amongst non-problematic ecstasy users, ecstasy (35.5%) and 
cocaine (33.9%) was also reported as having played a strong part, whilst amongst problematic 
ecstasy users this life change was more often attributed to ecstasy than alcohol (45.3% vs. 28.3% 
respectively).  A decrease in fear was also attributed mostly to alcohol compared to any other 
drug, amongst drug naïve (12.6%), cannabis controls (32.3%) and non-problematic ecstasy user 
(32.3%) groups.  
 
Increased feelings of well-being were also attributed to alcohol amongst polydrug controls (21%) 
and non-problematic ecstasy users (25.8%), but also to cannabis (24.2%) in the cannabis using 
controls, whilst amongst non-problematic ecstasy users, ecstasy (25.8%) and cocaine (27.4%) 
were strongly implicated.  Ecstasy was the strongest drug implicated (35.8%) in feelings of well-
being with problematic ecstasy users. 
 
Cannabis was reported as the reason behind enhanced sensations, by 22.6% of cannabis using 
controls, yet ecstasy appeared to be the drug that non-problematic (54.8%) and problematic 
ecstasy users (56.6%) attributed this change to the most, with LSD, cocaine and cannabis also 
being implicated in these two ecstasy using groups.  Ecstasy use was also commonly linked to 
 changes in spiritual enlightenment in both of these groups (27.4% of non-problematic and 30.2% 
problematic ecstasy users), although non-problematic ecstasy users reported LSD to have 
contributed equally to this change.  As expected, increased empathy was attributed to ecstasy 
more than any other drug amongst non-problematic and problematic ecstasy users (45.2% and 
45.3% respectively), as was a decrease in defensiveness amongst problematic ecstasy users 
(35.8%). 
 
 Specific Drugs and Attributions to Negative Life Experience Changes  
 
Aggression appeared to be strongly associated with alcohol compared to any other drug and 
across all groups, with 24.2% of cannabis controls, 32.3% ecstasy users and 26.4% problematic 
users attributing this change to alcohol.  Paranoia was most strongly associated with cannabis, 
compared to other drugs and across groups, with 21% of cannabis controls, 25.8% ecstasy users 
and 49.1% problematic ecstasy users implicating cannabis in this change.  However, problematic 
ecstasy users also attributed paranoia quite highly to ecstasy (34%) and amphetamine (30.2%) 
use. 
 
Cannabis use also appeared to be a strong factor compared to any other drug for motivational 
problems and loss of sociability in both non-problematic ecstasy (30.6% and 22.6% respectively) 
and problematic ecstasy users (32.1% and 39.6%). Cannabis was also implicated in perceptions 
of concentration loss amongst problematic ecstasy users (24.5%) and also with memory loss 
amongst non-problematic ecstasy users (27.4%) compared to a low implication of ecstasy 
attributed to memory loss in this non-problematic and problematic ecstasy users (only 4.8% and 
13.2% respectively). 
  
Hallucinations were mainly reported by problematic ecstasy users but were equally attributed to 
ecstasy and LSD use (24.5%).  This is probably because this group reported significantly greater 
consumption levels of both ecstasy and LSD compared to the other drug using groups.   
 
Ecstasy was a very strong attributional factor linked negatively perceived changes in depression 
(62.3%), anxiety (37.7%), panic attacks (34%), general illness (39.6%) and weight loss (49.1%) 
amongst problematic ecstasy users.  Amongst this group, ecstasy was also implicated in 
obsessive thoughts, alongside cannabis use (30.2%).  Whilst in the non-problematic user group, 
far fewer participants linked their ecstasy use to these negative symptoms.  Mood swings were 
also strongly attributed to ecstasy, amongst ecstasy and problematic ecstasy users (25.8% and 
54.7% respectively), but so too were the stimulants, cocaine and amphetamine.  Similarly both 




Parrott et al (2001) and Milani et al (2005) showed that psychiatric symptoms and 
psychobiological problems were associated not only with ecstasy/MDMA use, but also with 
recreational polydrug use.  The current exploratory survey investigated the issue of polydrug use 
with regard to long term ‘off-drug’ psychological and physical effects reported by recreational 
drug users.  It sought to determine which drugs, if any, were associated with the long-term effects 
reported by some ecstasy-polydrug users and whether problematic and non-problematic ecstasy 
users differed with respect to what problems they attributed to particular drugs or drug 
combinations. 
  
The study demonstrated that polydrug use does play a role in the effects commonly associated 
with ecstasy use, referred to here as positive and negative life changes. A significantly greater 
number of cannabis controls and ecstasy users reported life changes compared to non-drug users 
in a number of positive and negative areas, and further still attributing these more to drug use 
than ‘other factors’, suggesting that polydrug use certainly plays a role in attributions related to 
changes in life experiences.  Amongst the drug using groups (cannabis and ecstasy user groups), 
the ecstasy users reported the greatest number of changes and in some areas i.e. panic attacks, 
depression, paranoia and general illness, problematic ecstasy users reported more changes 
compared to non-problematic ecstasy users.   The fact that fewer cannabis using controls reported 
changes compared to ecstasy users could reflect that ecstasy rather than polydrug use is more 
associated with these effects, however, levels of polydrug use are significantly higher in both 
ecstasy using groups compared to the cannabis controls.  This strongly supports previous studies 
suggesting that the heavier the ecstasy use, the heavier the polydrug use (Scholey et al, 2004) and 
as such, these effects can not solely be attributed to ecstasy, based on these group differences in 
life changes. 
Whether drug user’s attributed changes to a single drug or a number of drugs was also explored.  
Cannabis using controls who reported changes, and attributed these to drug use, tended to 
attribute the change to just the one drug, which tended to be cannabis or alcohol, rather than both.  
This isn’t surprising given the limited use of other drugs in this group (see table 1).  In 
comparison, the ecstasy using groups tended to report a combination of drugs as influencing the 
reported changes (both positive and negative), more so for the problematic ecstasy users.   Of the 
drugs reported ecstasy did appear to play a strong attributional role, especially for problematic 
ecstasy users with regard to depression, anxiety, panic attacks, general illness and mood swings.  
 However, this could simply be due to the nature of the study, and potential priming in these 
participants from completion of earlier questions on the patterns of ecstasy use and whether they 
indicated problems associated with their past use, specifically for problematic ecstasy users.  
Whilst this is a possibility to some extent, the strong attributional role of ecstasy, particularly in 
these areas is consistent to previous research (Parrott et al, 2002; Rodgers et al, 2006).   Whilst 
ecstasy is a strong attributional role for a lot of the changes reported by the ecstasy users, what is 
interesting is that when investigated further, especially amongst the problematic ecstasy users,  it 
is not the only drug which plays a role in reported problems, rather a range of drugs are strongly 
implicated.   These other drugs include  alcohol, amphetamine and cocaine and especially 
cannabis, which participants associated with negative changes such as paranoia, memory loss, 
concentration loss, motivational problems and obsessive thoughts.  The role of these and other 
drugs in ecstasy-attributed effects was not covered by Parrott et al (2004) or  Rodgers et al 
(2006), but is consistent with the findings that elevated psychopathology in ecstasy users is 
associated with polydrug use (Medina and Shear, 2007), and in some cases specifically cannabis 
(Daumann et al, 2001; Morgan et al, 2002; Rosier & Sahakian, 2004; Daumann et al, 2004).  
Thus, data from the current study, taken together with these previous reports highlight the 
important possible confounding effects of polydrug use in research attempting to explore and 
characterise the extent and nature of MDMA/ecstasy-related effects. 
 
As previously discussed there were differences in drug attributions between the ecstasy using 
groups (non-problematic and problematic).  The fact that problematic ecstasy users reported more 
changes and attributed these more to ecstasy than other drugs, over and above non-problematic 
ecstasy users is not surprising given that these ecstasy users identify themselves as ‘having 
psychological problems’ which they attribute to past ecstasy use.   It is possible that these 
problematic ecstasy users were experiencing these problems prior to their ecstasy use given that a 
 greater number of problematic ecstasy users reported psychiatric histories compared to non-
problematic ecstasy users; an account previously acknowledged by the authors (Soar & Parrott, 
2002; Soar et al, 2006).  Suggesting that pre-existing problems could be the cause of the drug use 
rather than the consequence; this has previously been shown by Lieb et al (2002) who reported 
that in a majority of cases ecstasy and other drug use was actually secondary to the onset of 
psychological problems.   However, more recently Alati et al (2008) have prospectively shown 
that the psychopathology, such as anxiety and depression, did not precede ecstasy use.  Whether 
the problems reported by problematic ecstasy users within this current study preceded or 
followed ecstasy user, is impossible to conclude based on the retrospective nature of the current 
study.   
 
It is possible that the reported differences between problematic and non-problematic ecstasy users 
could be accounted for by an attribution bias, and this could further explain why some ecstasy 
users do not report problems despite showing evidence that their psychological performance is 
impaired (Fox et al 2001).  Attributional style itself can be influenced by medical and psychiatric 
history (Robbins and Kirmayer, 1991), and indeed individual psychological health at the time of 
reporting of symptoms/changes in experiences could influence questionnaire responses, 
especially if those problematic ecstasy users are still experiencing their reported problems.  There 
is some indication of this from the psychopathological profiles of these problematic ecstasy users 
(reported in a previous paper, Soar et al, 2006), which indicated that scores on the Brief 
Symptom Inventory (BSI; Derogatis and Melisaratos, 1983) for these participants were 
significantly higher compared to the non-problematic ecstasy users, specifically on the 
somatisation, depression and anxiety subscales. 
 
 The current study has shown that other drug use is often attributed as being responsible for 
effects which have previously been described in numerous reports as being due to 
ecstasy/MDMA.  This adds to the view that isolating the specific effects of ecstasy in recreational 
drug users is difficult, if not impossible. To complicate the issue further different patterns of 
polydrug use, consumed in combination with or directly following and/or preceding ecstasy use 
could influence the reporting of specific ecstasy-related effects and potential problems.  Sumnall 
et al (2004) reported that 68% of the clubbers they interviewed regularly mixed a variety of 
drugs; the most popular combinations being cannabis, alcohol, ecstasy and amphetamines.     
Therefore, the complex interactions between drugs need to be considered, as well as their 
possible additive effects (Parrott, 2006; Gouzoulis-Mayfrank, 2006; Parrott et al, 2007).    At 
present little is known of the psychopharmacological effects of combining drugs.    Hernandez-
Lopez et al (2002) reported that MDMA used in combination with alcohol induced longer lasting 
euphoria and well-being than MDMA or alcohol alone, whilst MDMA actually reversed the 
subjective sedation induced by alcohol; and  Verheyden et al (2003) reported that participants 
who took cannabis, alcohol and cocaine in conjunction with ecstasy reported higher scores for 
acute positive effects of the drug, suggesting that the subjective pleasurable effects of these drugs 
are additive.  Further still, they showed that users who had used cocaine in conjunction with their 
ecstasy use scored higher on the acute negative and positive effects compared to ecstasy users 
that had not used cocaine, whereas those who had used amphetamine and ecstasy together 
reported higher physical effects than those that had not.   These findings may be of possible 
significance within the current study, and may explain why the ecstasy using groups  within the 
current study reported ecstasy-related effects more to a combination of drugs than to single drug 
use.   
 
 As with the majority of research assessing the effects of recreational ecstasy polydrug use there 
are a number of methodological limitations that need to be acknowledged (for a detailed 
discussion see Curran, 2000).   Profiles of individual’s ecstasy and other drug use were based 
solely on self-report data with no biological assays to verify this data.  Self-report data is not 
always reliable.  These reports are unlikely to be wholly accurate and may often underestimate or 
overestimate drug consumption.  They may also under- or overestimate their usage either because 
of fears about confidentiality or to heighten their ‘street credibility’.  Further still only lifetime 
estimations of other drug use were reported and similar questions akin to those asked of ecstasy 
users (e.g. average consumption and maximum consumption on each occasion and duration of 
usage) also need to be asked pertaining to patterns of other drug use, in order to establish 
specifically the contributing role, if any, of other drug use.   
 
In this study there was also no objective assessment to show that participants were ‘drug-free’ at 
the time of completing the questionnaires.  Even if they were drug free at the time of completion, 
there is the potential that rather than just reflecting on the long-term ‘off-drug’ effects, responses 
may have been affected by residual, sub-acute drug effects (Verheyden et al, 2003; Curran, et al, 
2004).  
 
The Life Experiences Questionnaire was developed from identifying the common psychological 
and physical effects associated with ecstasy use, from a review of the empirical and subjective 
reports on ecstasy users (Liechti et al 2000; Gamma et al, 2000; Cami et al, 2000; Liechti and 
Vollenweider, 2001; Cohen et al, 1995; Parrott et al, 2002).  Labelling the questionnaire as ‘Life 
Experiences’, without reference to the identified items being known effects of ecstasy, allowed 
these effects to be explored in relation to other drug use, as well as ecstasy;  thus, exploring the 
perceptions and attributions to different drugs amongst polysubstance users themselves.   Given 
 that the Life Experiences questionnaire was devised specifically for this exploratory study, its 
validity and reliability needs to be fully determined in other samples of polysubstance users.  
However, support that this questionnaire does reliably detect life changes in ecstasy users and the 
distinction between problematic and non-problematic ecstasy users, comes from data on the 
psychopathological profiles of these users, reported in Soar et al (2006).  However, the forced 
choice nature of the questionnaire limits participant responses and participant’s interpretations of 
these questions could have also differed to that intended by the researchers. A semi-structured 
questionnaire or follow up interviews could provide more detailed information, and also explore 
other effects attributed to drug use rather just the psychological and physical effects of these 
substances, e.g. social aspects and lifestyle issues surrounding drug use, which too could 
influence the reporting of problems/changes in individuals lives. 
 
The current study allocated ecstasy users to one of two groups (problematic and non-problematic 
ecstasy user) based on the response to a single question, ‘Have you experienced any problems, 
which you attribute to your ecstasy use?’  As pointed out by one of the reviewers, this question 
could be interpreted in a number of ways with participants attributing a wide range of problems 
including psychological, physical, social, economic etc. to their use of ecstasy.    Whilst it is 
acknowledged by the authors that this is somewhat of a crude classification system, it replicates 
the method used by Fox et al (2001) who also asked participants to give some qualitative 
information regarding their problems.  The common problems reported related predominantly to 
the psychological effects associated with the drug, such as low mood, depression and anxiety and 
cognitive difficulties.  Additional evidence to suggest this single question has some validity also 
comes from the psychopathological profiles of these problematic ecstasy users compared to non-
problematic ecstasy users, as measured by a standardised and validated measure – the BSI (Soar 
et al, 2006), suggesting that the problematic ecstasy users within this study were showing signs of 
 psychological problems over and above the non-problematic ecstasy and cannabis using controls.  
However, this still does not provide objective confirmation that the life changes reported by the 
drug users within this study have actually occurred.   The significance of this objective 
confirmation of problems is somewhat trivial considering that individuals actually perceive 
themselves to have experienced certain changes, and in some these changes are perceived to be 
problematic to the extent that some of them are seeking help and advice from professional 
organisations.  Taken together, this highlights that the individual’s perception of their experiences 
and problems are important when addressing drug-attributed effects. However, there may also be 
some individuals that are displaying problems and through poor self-awareness and/or the lack of 
recognition and perception of these problems (Parrott et al, 2002; Sumnall et al, 2004), may not 
be reporting them or more importantly seeking help for them. 
 
Overall, whether one can objectively confirm the effects related to drug use or not, the current 
study reported that both ecstasy using groups reported greater polydrug use than cannabis using 
controls and that they also attributed more life changes, both positive and negative to a range of 
drugs rather than specifically just ecstasy.  This data supports the important role of polydrug use 
and attributions in ecstasy-related effects and as such future research into the psychological 
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